BioTime, Inc. (NYSE Amex:BTIM) today reported financial results for the quarter ended June 30, 2010 and provided an update on recent corporate developments.

For the three months ended June 30, 2010, total revenue (including royalty income, revenue recognition of deferred license fees, and grant income) was $680,278, up 57% from $432,090 for the same period one year ago. For the six months ended June 30, 2010, total revenue (including royalty income, revenue recognition of deferred license fees, and grant income) was $1,447,406, up 99% from $728,833 for the same period one year ago. These increases in revenue are primarily attributable to our receipt of a $395,096 quarterly installment of our $4.7 million research grant from the California Institute of Regenerative Medicine in each of the first two quarters of 2010. The net loss for the three months ended June 30, 2010 was $2.3 million, or ($0.06) per share, compared to a net loss of $1.5 million or ($0.05) per share for the three months ended June 30, 2009. Net loss for the six months ended June 30, 2010 was approximately $3.5 million, compared to a net loss of approximately $3.0 million for the six months ended June 30, 2009. Increases in net loss in 2010 reflect increases in research and development as we continued to expand our stem cell research program, and also reflect increases in other operating expenses.

Cash and cash equivalents totaled $18.1 million as of June 30, 2010, compared with $12.2 million as of December 31, 2009. During the six months ended June 30, 2010, BioTime received $9,041,403 in net cash from financing activities, including $150,422 received in connection with the exercises of 90,702 options and $8,890,981 received in connection with the exercises of 4,838,942 warrants.

For the three and six months ended June 30, 2010, BioTime recognized, respectively, $215,293 and $512,294 in royalty revenue from the sale of Hextend ®, BioTime’s proprietary physiologically balanced blood plasma volume expander for treating low blood volume, a condition often caused by blood loss during surgery or by trauma. This compares to royalty revenue from the sale of Hextend of $351,724 and $574,391 during the three and six month periods, respectively, ended June 30, 2009. The decrease in royalties is primarily attributable to a decrease in sales to the United States Armed Forces by Hospira.

“Our goals for 2010 include increasing revenue from the sale of our stem cell research products; ramping up our first programs for the development of stem cell therapeutic products through our subsidiaries OncoCyte Corporation and OrthoCyte Corporation, and pursuing development and marketing opportunities through ES Cell International Pte Ltd, a Singapore stem cell company that we acquired during our second quarter,” said Michael West, Ph.D., our President and CEO. We are now offering 36 novel stem cell lines through our subsidiary Embryome Sciences, Inc. and we plan to introduce 62 additional cell lines and associated media, matrices, and conditioned media for a total of 299 research products marketed during the second half of the year. Our therapeutic product development efforts at OncoCyte are focused on creating genetically modified stem cells designed to target and destroy malignant tumors, while the initial focus of our work at OrthoCyte is the development of stem cells that have the capability to regenerate cartilage and other connective tissues. Arnold I. Caplan, Ph.D., Professor of Biology and General Medical Sciences and director of the Skeletal Research Center at Case Western Reserve University, has joined OrthoCyte on a part-time basis as its Chief Scientific Officer while maintaining his faculty position. Dr. Caplan is an internationally renowned scholar in the field of musculoskeletal research.

“We will also be expanding our work with induced pluripotent stem cell or “iPS” technology. Earlier this year, our scientists co-authored a scientific paper titled “Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcriptional Reprogramming,” which was published in the peer-reviewed journal Regenerative Medicine. The paper explains the use of iPS technology to reverse the developmental aging of normal human cells. Using precise genetic modifications, normal human cells were induced to reverse both the “clock” of differentiation (the process by which an embryonic stem cell becomes the many specialized differentiated cell types of the body), and the “clock” of cellular aging (telomere length). As a result, aged differentiated cells became young stem cells capable of regeneration. These findings may have significant implications for the development of new classes of cell-based therapies targeting age-related degenerative disease,” continued Dr. West.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly-owned subsidiary, Embryome Sciences, Inc. BioTime’s subsidiary OncoCyte Corporation focuses on the therapeutic applications of stem cell technology in cancer. BioTime also plans to develop, through its subsidiary, BioTime Asia, Limited, therapeutic products in China for the treatment of ophthalmologic, skin, musculo-skeletal system, and hematologic diseases, including the targeting of genetically modified stem cells to tumors as a novel means of treating currently incurable forms of cancer. BioTime is also seeking to develop therapeutic applications of stem cells to treat orthopedic diseases and injuries through its newly formed subsidiary OrthoCyte Corporation. On May 3, 2010, BioTime also acquired ES Cell International Pte. Ltd. (“ESI”), a Singapore private limited company. Established in 2000, ESI focuses on hES technology, and is a distributor of hES cell lines to the research community. ESI holds over 49% of the shares of Cell Cure Neurosciences Ltd. (“Cell Cure”), an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, and technology for use in surgery, emergency trauma treatment, and other applications. BioTime’s lead product, Hextend ®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime can be found on the web at

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:




June 30,2010 (unaudited)
  December 31,

Cash and cash equivalents $ 18,056,089 $ 12,189,081
Inventory 49,478 38,384
Prepaid expenses and other current assets   880,571   138,547  
Total current assets 18,986,138 12,366,012
Equipment, net of accumulated depreciation of $85,496 and $54,291, respectively 339,418 131,133
Deferred license and consulting fees 2,165,700 880,000
Deposits 51,900 55,926
Intangible assets, net   12,603,756   -  
TOTAL ASSETS $ 34,146,912 $ 13,433,071  
Accounts payable and accrued liabilities $ 795,505 $ 530,958
Deferred grant income 263,397 263,397
Deferred license revenue, current portion   323,581   367,904  
Total current liabilities   1,382,483   1,162,259  
Deferred license revenue, net of current portion 1,121,693 1,223,823
Preferred Shares, no par value, authorized 1,000,000 shares; none issued - -
Common shares, no par value, authorized 75,000,000 shares; issued and outstanding shares: 39,980,703 and 33,667,659 at June 30, 2010 and December 31, 2009, respectively 83,989,113 59,722,318
Contributed capital 93,972 93,972
Accumulated other comprehensive loss (5,910 ) -
Accumulated deficit   (56,315,757 )   (52,769,891 )
Total shareholders’ equity 27,761,418 7,046,399
Noncontrolling interest   3,881,318   4,000,590  
Total equity   31,642,736   11,046,989  
TOTAL LIABILITIES AND EQUITY $ 34,146,912 $ 13,433,071  



Three Months Ended Six Months Ended

June 30,2010

June 30,2009

June 30,2010

June 30,2009
License fees $ 58,216 $ 73,226 $ 131,442 $ 146,452
Royalties from product sales 215,293 351,724 512,294 574,391
Grant income 395,095 6,800 790,191 6,800
Other revenue   11,674     340     13,479     1,190  
Total revenues   680,278     432,090     1,447,406     728,833  
Research and development (1,429,027 ) (639,594 ) (2,588,978 ) (1,165,418 )
General and administrative   (1,566,675 )   (900,146 )   (2,499,973 )   (1,582,320 )
Total expenses   (2,995,702 )   (1,539,740 )   (5,088,951 )   (2,747,738 )
Loss from operations   (2,315,424 )   (1,107,650 )   (3,641,545 )   (2,018,905 )
Interest expense (99 ) (365,539 ) (157 ) (973,566 )
Other income/(loss)   (38,263 )   1, 819     (24,108 )   2,887  
Total other income/(expenses), net (38,362 ) (363,720 ) (24,265 ) (970,679 )
NET LOSS (2,353,786 ) (1,471,370 ) (3,665,810 ) (2,989,584 )
Less: Net loss attributable to the noncontrolling interest $ 94,011   $ -   $ 119,272   $ -  
Net loss attributable to BioTime, Inc. $ (2,259,775 ) $ (1,471,370 ) $ (3,546,538 ) $ (2,989,584 )
Foreign currency translation loss   (5,910 )   -     (5,910 )   -  
COMPREHENSIVE NET LOSS $ (2,265,685 ) $ (1,471,370 ) $ (3,552,448 ) $ (2,989,584 )
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.06 ) $ (0.05 ) $ (0.10 ) $ (0.11 )
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED   37,562,372     27,085,454     35,651,404     26,199,630  

Copyright Business Wire 2010